Anticholinergic bladder drugs were associated with an increased risk of dementia compared with nonuse, but not when compared with the beta-3 agonist mirabegron.
The finalization of new criteria for the "healthy" nutrient content claim on food labels has been delayed, allowing more time for regulatory review of standards that could significantly influence labeling practices and help reduce diet-related chronic diseases.